Case Report
Evaluation of Anticancer Potential of the Unorthodox Homeopathic Nosode, HIV-30c, in A549 Cancer Cells: a Commentary on our Recently Published Research
Anisur Rahman Khuda-Bukhsh*
Department of Zoology, University of Kalyani, India
*Corresponding author: A.R. Khuda-Bukhsh, Khuda-Bukhsh Homeopathic Benevolent Foundation, India
Published: 17 Dec, 2017
Cite this article as: Khuda-Bukhsh AR. Evaluation of
Anticancer Potential of the Unorthodox
Homeopathic Nosode, HIV-30c, in
A549 Cancer Cells: a Commentary on
our Recently Published Research. Clin
Oncol. 2017; 2: 1387.
Abstract
A homeopathically prepared remedy, HIV nosode 30c was tested for its possible anticancer potential
and therapeutic use against cancer as revealed from a recent study on A-549 lung cancer cells
conducted in our lab by deploying certain molecular biology protocols that yielded some interesting
and promising results. The implications of the study in regard to its possible practical application
as an integrative therapy in oncology and on the understanding of the molecular mechanism of
biological action of the ultra-highly diluted homeopathic drugs are pointed out.
Keywords: HIV 30c nosode; Therapeutic use; Anti-cancer potential; A549 lung cancer cell
Introduction
The Human Immunodeficiency Virus (HIV) is the causal organism for inducing the Acquired
Immune Deficiency Syndrome (AIDS), commonly known as the AIDS disease. AIDS appeared for
the first time in the 1980s. The retrovirus HIV infects human being and initially produces a brief
period of influenza-like illness and then usually remains in the host without apparently showing
any other typically detectable symptom(s) of its own. Soon it replicates their single stranded DNA
to form double-stranded cDNA by reverse transcriptase activity and gets incorporated into the
host genome without producing any more notable diagnostic symptom for a variable period of
time [1]. Then, along with the transcription of the host genome, the incorporated viral DNA also
starts transcribing the viral genes, the product of which begins to cause a progressive loss of CD4+
T-cells of the host, leading to almost total dysregulation of the host immune system. The host now
becomes extremely susceptible to common infections, like tuberculosis, and other opportunistic
infections and tumours, the most notable among them being the infection of the lung that leads
to the condition known as “pneumocystis pneumonia”, a disease associated with severe weight
loss and skin lesions mainly caused by Kaposi’s sarcoma, or by other AIDS-related conditions [2].
Kaposi’s sarcoma had earlier been suspected to be produced by human herpesvirus 8 (HHV8), also
known as Kaposi Sarcoma-associated Herpes Virus (KSHV) or KS agent in the 19th century [3]. but
the viral origin of the disease was actually confirmed only in 1983 when the AIDS disease started
spreading like an epidemic [4]. Therefore, apart from its primary effect on the immune system, the
patients with the AIDS disease often end up showing severe secondary lung infection, caused by
Kaposi sarcoma with timorous growth, which often turns cancerous in nature.
The AIDS disease rapidly spread in the 1980s killing thousands of patients and no proper
treatment could be found at hand for a long time to combat this dreadful disease owing to
unavailability of any proper anti-viral drug or specific strategy for effective control and treatment.
As reverse transcriptase activity is extremely important for retro-virus replication for entry into the
host genome, orthodox drugs like some reverse transcriptase inhibitors, or protease inhibitors were
tested [5,6]. But while they showed their ability to interrupt the virus from replicating as expected,
unfortunately because of their severe side-effects, these drugs had to be soon withdrawn or their use
could no longer be recommended for AIDS.
Two major hallmarks of cancer cells are their acquired property of immortalization and
uncontrolled cell division, among others. For continuous and rapid cell division, one pre-requisite is
the continuous synthesis of the telomeres (chromosome ends) that determines the precise time when
the chromosome is ready for the next division. Therefore, one of the other characteristic features of
the cancer cells is their ability to drive the telomere synthesis faster to cope up with the urge of the
cancer cells to divide and re-divide. Telomerease is the specific enzyme that helps in this activity
of the telomere synthesis. For the divisional activity of the telomere
zone of the chromosome, the Telom Erase Reverse Transcriptase
(TERT) enzyme forms a part of the sub-unit which is activated and
expressed more in order to help the rapid synthesis of the telomeres
of chromosomes [7] to facilitate faster division. For the synthesis
of the two-stranded cDNA structure from the single stranded viral
RNA, the reverse transcriptase enzyme is also necessary. Therefore,
anything that inhibits the expression of TERT gene, is significant not
only for its direct role in inhibition of telomerase activity, but also
for its effective anti-retroviral role in preventing cDNA formation
and thereby incorporation into the host genome. Similarly, certain
enzymes are critically needed for the DNA synthesis and replication
process. Topoisomerase II (Top II) is one among them that can serve
as a marker for the efficiency of perfect DNA replication process
necessary for the cell division [8]. Therefore, stopping the ability of
the DNA replication process should contribute towards restricting
the process of cell division at a crucial stage, that has also been
recognized as a legitimate target for all the anti-cancer drugs.
If and when, the cancer cells bypass all opposing forces of cell
division, there is also an intrinsic mechanism to kill these errant
cells by a mechanism of programmed cell death (apoptosis) or by
necrosis or autophagy [9]. For inducing apoptosis, which is basically
controlled by the ratio of the pro-apoptotic signals (like Bax,
Caspase-3, Cytochrome c etc.) and anti-apoptotic signals (like Bcl2,
TERT, Top II), these defiant dividing cancer cells are directed to the
apoptotic pathway mainly through the action of the “gate-keeper”
gene, the p53. Therefore, the study of relevant signalling pathway
markers can give important clues about the molecular event/status
if the cells are undergoing the apoptotic pathway. Any drug that can
increase the apoptosis may be suggested as opposing the carcinogenic
process.
Nosodes are highly diluted homoeopathically prepared drugs
using biological materials such as diseased tissues, organisms, cultures
(bacteria, fungi, and viruses), or parasites, or from decomposed
products from humans or animals as the primary source material of
the drug. In homeopathic practices, more than forty-five such nosodes
have so far been in use since 1830 [10]. These nosodes are generally
used in highly-diluted forms and known to be non-toxic in nature.
Though clinical benefits of nosodes have often been experienced by
homeopathic practitioners and patients, not many of them have been
scientifically tested for their claimed efficacy [11-13]. HIV nosode 30c
(henceforth to be called HIV-30) was developed from the sera of two
serologically confirmed AIDS-infected volunteers as per the principal
guidelines suggested by Samuel Hahnemann [14] and approved
by the Technical Committee of CCRH, New Delhi, Government
of India [15,16] and the Homeopathic Guidelines of Drug Proving
by the European Committee of Homeopathy through an elaborate
15-step safe method [17]. The standard homeopathic procedure of
potentization elaborated in Khuda-Bukhsh [18]) was followed to
obtain the 30c potency (the dilution factor being 1060) using water/
ethanol as solvent/vehicle after taking the statutory recommended
precautionary measures. This dilution factor of 1060 in the potency 30c
would suggest that even existence of a single molecule of the original
nosode material is highly improbable in the drug. The HIV-30 was
mixed with the media in three different doses, namely, the 50% lethal
dose (LD50)(3.5ml/ 100 ml media) and two doses below the LD50
(at 3ml/100 ml media and 2.5 ml/100 ml media, respectively) for
further experiments; Dose-1, -2 and -3 were designated from lowest
to highest dose. The cells treated with succussed ethanol from the
same stock with which the drug was prepared served as the control.
Although initial testing of efficacy of the HIV-30 was done on
three different cancer cell lines- HeLa (cervical cancer), HepG2 (liver
cancer), A 549 was (lung cancer) and on the normal liver hepatocytes,
WRL68 cells (control) procured from National Centre for Cell
Science (NCCS), Pune, India and maintained separately in DMEM
containing 10% heat-inactivated FBS and 1% antibiotic mixture for
cell culture in a humidified incubator with ambient O2 level and 5%
CO2 level at 37ºC, subsequently detailed analysis deploying various
other specific protocols was carried out only on the liver cancer A549
cells, keeping WRL-68 normal liver cells as control.
Multiple routine standardized procedures used for authentic
evaluation of anti-cancer potential, like cell viability (MTT) assay, cell
morphological observation, apoptotic analysis, nuclear morphology
analysis by DAPI staining, drug-DNA interaction analysis by circular
dichroism spectroscopy, DNA fragmentation assay, determination
of Reactive Oxygen Species (ROS) generation and accumulation,
analysis of changes of Mitochondrial Membrane Potential (MMP),
proliferation assay, migration assay, analysis of b-galactosidase
associated senescence, analysis of expressions of proteins related
to cytotoxicity by Western blot including analysis of expression of
telomerase reverse transcriptase (TERT) and topoisomerse II (Top
II) associated with DNA/cell replication, as may be found in the
original paper [18] were considered for understanding the cellular
and mechanistic principles behind the efficacy of the drug. Statistical
support was provided wherever necessary. These parameters of study
are the known indicators of the status of cell division, migration
and metastasis, and also cell death. The effects of HIV 30 nosode in
the A549 cells vis-à-vis WRL-68 cells were analyzed as compared to
that of the other control arm, the succussed alcohol 30c. The overall
results clearly established anticancer potential of HIV-30, and also
demonstrated its ability to inhibit the expression of both TERT and
Top II signal proteins. The favourable modulation of both these
proteins would strongly suggest that HIV-30 had the ability to
inhibit not only the cancer cell division principally through decrease
in telomere synthesis, which is a pre-requisite for cell division, but
also indicative of the possible role it could play in the prevention or
slowing down of the formation of the double stranded cDNA from
the single stranded retro-viral RNA.
Although how the microdoses of the homeopathic remedy HIV-
30 could alter various pathological conditions is still not fully resolved.
However, several aspects related to research outcome on efficacy and
on the question of understanding how the miniscule dose of the ultrahighly
diluted homeopathic remedy can produce regulatory influence
through possible epigenetic modifications have been elaborately dealt
with in several of our earlier publications [19-28] after the present
author first proposed the hypothesis [29] in 1997 that the ultrahighly
diluted homeopathic drugs possibly acted through regulation
of gene expression by an effective intrinsic molecular mechanism by
triggering a cascade of gene action in a regulatory manner. Recently
this “gene regulatory hypothesis” is steadily gaining ground and has
also been supported as the most plausible and correct hypothesis in
explaining the molecular mechanism of the potentized homeopathic
drugs in all living systems, both in plants and animals and both in vivo
and in vitro conditions. This hypothesis has been supported by some
other prominent workers in the allied field of research [30]. Further
works in elucidating more precisely the mechanism and pathway(s) of
action of different homeopathically diluted drugs have now become
an exciting area of research.
Support for work: The original work was done by utilizing UGC
grants No. (F1-17.1/2012-13/MANF-2012-13- MUS-WES-13662/
(SA-III/Website) Dated 28-Feb-2013) and F.6-6/2013-14/
EMERITUS-2013-14-GEN-2067/(SA-II) dt. 18th April, 2014). Sincere
thanks are due to Dr. Arindam Bhattacharyya, Associate Professor,
Department of Zoology, Calcutta University, for his kind help in
performing the confocal microscopy.
References
- Sepkowitz KA. AIDSdthe first 20 years. N Engl J Med 2004; 344: 1764-72.
- Kirch W. Encyclopedia of public health. New York: Springer 2008;676-7.
- Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis. 1872;4(2):265-273.
- Conte JE, Hadley WK, Sande M. Infection-control guidelines for patients with the acquired immunodeficiency syndrome (AIDS). N Engl J Med. 1983;309(12):740-4.
- Imamichi T. Action of Anti-HIV Drugs and Resistance: Reverse Transcriptase Inhibitors and Protease Inhibitors. Curr Pharm Des, 2004;10(32):4039-53.
- Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, et al. Administration of 3'-Azido-3'-Deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. The Lancet. 1886;1(8481):575-80.
- Mitchel M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E. Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nat Struct Mol Biol 2010;17(4):513-8.
- Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol. 2000;64:221-53.
- Aimee L Edinger, Craig B Thompson. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 2004;16(6):663-9.
- Shah R. Hepatitis C Nosode: the preparation and homeopathic pathogenetic trial. Homeopathy. 2013; 102(3):207-214.
- Mondal J, Samadder A, Khuda-Bukhsh AR. Psorinum 6× triggers apoptosis signals in human lung cancer cells. J Integr Med. 2016; 14(2): 143-53.
- Mondal J, Das J, Shah R, Khuda-Bukhsh AR. A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells (HepG2) in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathway. J Integr Med. 2016;14(3):209-18.
- Khuda-Bukhsh AR, Mondal J and Shah R. Therapeutic potential of HIV nosode 30c as evaluated in A549 lung cancer cells. Homeopathy. 2017;106(4):203-13.
- Hahnemann S. Organon of medicine. 6th edn. New Delhi: B. Central Council for Research in Homeopathy: general directions and instructions for proving of drugs. Jain Publ. 1979;190-212.
- European Committee for Homeopathy: homeopathic drug proving guidelines. 2004.
- Shah R. HIV Nosode: The homeopathic pathogenetic trial. Forsch Komplementmed. 2015;22(3):156-62.
- Khuda-Bukhsh AR, Mondal J, Shah R. Therapeutic potential of HIV nosode 30c as evaluated in A549 lung cancer cells. Homeopathy. 2017;1-11.
- Khuda-Bukhsh AR. Towards understanding molecular mechanisms of action of homeopathic drugs: an overview. Mol Cell Biochem. 2003; 253(1-2):339-45.
- Mallick P, Mallick JC, Guha B, Khuda-Bukhsh AR. Ameliorating effect of microdoses of a potentized homeopathic drug, Arsenicum Album, on arsenic-induced toxicity in mice. BMC Complement Altern Med. 2003 Oct 22;3:7.
- Khuda-Bukhsh AR. Laboratory research in homeopathy: pro. Integr Cancer Ther. 2006;5(4):320-32. Review.
- Khuda-Bukhsh AR, Pathak S. Homeopathic drug discovery: theory update and methodological aspect. Expert Opin. Drug Discov. 2008;3(8):979-90.
- Khuda-Bukhsh AR. Mice as a model for homeopathy research. Homeopathy. 2009 ;98(4):267-79.
- Khuda-Bukhsh AR. Current trends in ultra-high dilution research with particular reference to gene regulatory hypothesis: REVIEW. The Nucleus. 2014;57(1):3-17.
- Khuda-Bukhsh AR. An overview of our research in exploring some basic issues of Homeopathy: future scope. Indian J Res Homeopathy 2017;11(3):147-57.
- Khuda-Bukhsh AR, Sikdar S. Condurango 30C Induces Epigenetic Modification of Lung Cancer-specific Tumour Suppressor Genes via Demethylation. Forsch Komplementmed. 2015;22(3):172-9.
- Khuda-Bukhsh AR, Bhattacharyya SS, Paul S, Dutta S, Boujedaini N, Belon P. Modulation of Signal Proteins: A Plausible Mechanism to Explain How a Potentized Drug Secale Cor 30C Diluted beyond Avogadro's Limit Combats Skin Papilloma in Mice. Evid Based Complement Alternat Med. 2011; 2011:286320.
- Saha SK, Roy S, Khuda-Bukhsh AR. Ultra-highly diluted plant extracts of Hydrastis canadensis and Marsdenia condurango induce epigenetic modifications and alter gene expression profiles in HeLa cells in vitro. J Intgr Med, 2015; 13(6):400-11.
- Khuda-Bukhsh AR. Potentized homeopathic drugs act through regulation of gene-expression: a hypothesis to explain their mechanism and pathways of action in vivo. Complement Ther Med 1997; 5(1):43-6.
- Paolo Bellavite, Andrea Signorini, Marta Marzotto, Elisabetta Moratti, Clara Bonafini, Debora Olioso. Cell sensitivity, nonlinearity and inverse effects. Homeopathy 2015;104:139-60.
- Marzotto M, Bonafini C, Olioso D, et al. Arnica montana stimulates extracellular matrix gene expression in a macrophage cell line differentiated to wound-healing phenotype. PLoS One 2016; 11:0166340.